Report #2853643

Received Aug 11, 2025

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex: Unknown
Age: Age unknown
State: KS
Recovered: Unknown
Vaccinated: —
Onset: —
Days to onset: —
Hospital days: —

Vaccines (1)

Type	Name	Manufacturer	Dose	Lot	Route / Site
MNQ	MENINGOCOCCAL CONJUGATE (MENVEO)	NOVARTIS VACCINES AND DIAGNOSTICS	2	UNK	—

Symptoms (1)

Extra dose administered

Symptom narrative

2 doses 1 year apart; This non-serious case was reported by a other health professional via sales rep and described the occurrence of extra dose administered in a patient who received Men ACWY-CRM NVS (Menveo) for prophylaxis. Previously administered products included Menveo (received 1st dose one year apart). On an unknown date, the patient received the 2nd dose of Menveo. On an unknown date, an unknown time after receiving Menveo, the patient experienced extra dose administered (Verbatim: 2 doses 1 year apart). The outcome of the extra dose administered was not applicable. Additional Information: GSK Receipt Date: 01-AUG-2025 The reporter reported that they had a patient who received 2 doses of Menveo 1 year apart, which led to extra dose administered The reporter asked were there any significant issues with receiving these within 1 year apart.